Bumetanide vs. Furosemide in Cirrhosis
This study is comparing two common medications, bumetanide and furosemide, which are both diuretics (water pills) used to treat fluid buildup in patients with cirrhosis (severe liver scarring). The researchers want to see how well each medication helps reduce fluid by measuring changes in your weight over 7 days. You might be able to join if you have cirrhosis and your doctor has ordered either bumetanide or furosemide for you within 24 hours of coming to the hospital. The study aims to enroll 500 participants, but its current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 500 participants. It compares two standard treatments, bumetanide and furosemide, given as ordered by your doctor.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your weight will be measured at 7 days to see how well the treatment is working.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Bumetanide vs. Furosemide in Cirrhosis
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Stacy A Johnson, MD · PRINCIPAL_INVESTIGATOR · University of Utah
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Percent change in weight7 days
Percent change in weight measured in kilograms from date of emergency department presentation (Day 0) to Day 7 of hospitalization, or date of discharge, whichever is earlier